Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes.
Ward GA, Dalton RP 3rd, Meyer BS, McLemore AF, Aldrich AL, Lam NB, Onimus AH, Vincelette ND, Trinh TL, Chen X, Calescibetta AR, Christiansen SM, Hou HA, Johnson JO, Wright KL, Padron E, Eksioglu EA, List AF. Ward GA, et al. Among authors: list af. Int J Mol Sci. 2023 Feb 15;24(4):3896. doi: 10.3390/ijms24043896. Int J Mol Sci. 2023. PMID: 36835307 Free PMC article.
Myelodysplastic syndromes.
List AF, Vardiman J, Issa JP, DeWitte TM. List AF, et al. Hematology Am Soc Hematol Educ Program. 2004:297-317. doi: 10.1182/asheducation-2004.1.297. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561689 Review.
Developmental therapeutics for myelodysplastic syndromes.
Naing A, Sokol L, List AF. Naing A, et al. Among authors: list af. J Natl Compr Canc Netw. 2006 Jan;4(1):78-82. doi: 10.6004/jnccn.2006.0008. J Natl Compr Canc Netw. 2006. PMID: 16403406 Review.
Biology and treatment of the 5q- syndrome.
Padron E, Komrokji R, List AF. Padron E, et al. Among authors: list af. Expert Rev Hematol. 2011 Feb;4(1):61-9. doi: 10.1586/ehm.11.2. Expert Rev Hematol. 2011. PMID: 21322779 Review.
The 5q- syndrome: biology and treatment.
Padron E, Komrokji R, List AF. Padron E, et al. Among authors: list af. Curr Treat Options Oncol. 2011 Dec;12(4):354-68. doi: 10.1007/s11864-011-0165-1. Curr Treat Options Oncol. 2011. PMID: 21964863
Erythropoietin receptor signaling is membrane raft dependent.
McGraw KL, Fuhler GM, Johnson JO, Clark JA, Caceres GC, Sokol L, List AF. McGraw KL, et al. Among authors: list af. PLoS One. 2012;7(4):e34477. doi: 10.1371/journal.pone.0034477. Epub 2012 Apr 3. PLoS One. 2012. PMID: 22509308 Free PMC article.
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion.
Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A. Wei S, et al. Oncogene. 2013 Feb 28;32(9):1110-20. doi: 10.1038/onc.2012.139. Epub 2012 Apr 23. Oncogene. 2013. PMID: 22525275 Free PMC article.
Advances in the management of myelofibrosis.
Komrokji RS, Verstovsek S, Padron E, List AF. Komrokji RS, et al. Among authors: list af. Cancer Control. 2012 Oct;19(4 Suppl):4-15. doi: 10.1177/107327481201904s04. Cancer Control. 2012. PMID: 23042420 Free article. Review.
305 results